Breast Cancer in Men: Clinical and Pathological Analysis of 817 Cases

Abstract

<jats:p> The objective of the current study was to describe breast cancer cases in men according to age, stage, and histology, calculating risks compared to women. It is a retrospective cross-sectional study of all breast cancer cases of the Hospital Cancer Registry of São Paulo state, Brazil, 2000–2015. Variables were age, sex, stage, and histology. Absolute numbers and proportions, Mann–Whitney test and prevalence ratio with 95% confidence interval were used. </jats:p><jats:p> The study included 93,737 cases, of which 817 were males. The mean age at diagnosis was 60.3 years in men and 56.2 years in women ( p &lt; .001). Stage II was the most common in both sexes (33.9% in men and 36.5% in women). Men had a higher frequency of stage III than women (PR 1.18, 95% CI 1.01–1.37). Stage 0 was significantly more common in women (PR 0.69, 95% CI 0.51–0.94). Ductal carcinoma and its variants were the most common histological types in both sexes (88.7% in men and 89.0% in women). Men had a higher frequency of rarer histological types such as papillary (PR 2.17, 95% CI 1.36–3.44) and sarcomas (PR 4.10, 95% CI 1.86–9.01). In conclusion, in men, breast cancer diagnosis occurred in more advanced ages and stages. Invasive ductal carcinoma was the primary histological type observed, although rarer types were more frequent. </jats:p>

Hemogram index parameters in the evaluation of male breast cancer and inflammatory response: a case-control study

“…The incidence of stage III/IV cancer at admission is >60% in Africa, <40% in North America and Western European countries, and between 40% and 60% in Eastern Europe and South America. The reasons for admission at later stages are reported to be race, low socioeconomic status, lack of awareness about the disease, and uncertainties in the characterization of highrisk patients for screening in the literature 8,[11][12][13][14][15][16][17] . In our study, the most common symptom was a breast mass, and 50% of them were at late stages at the time of diagnosis.…”

“…Patients with metastatic (stage IV) MBC are younger (≤65 years old), those with T1 tumors or those who have undergone surgical mastectomy have better survival rates than those who have not undergone a surgical intervention 20 . According to the immunohistochemical evaluation of the patients, 83-96% had ER+, 81-96% had PR+, and 10.6-35.1% were HER2 positive, and the most common histological type was IDC, which was observed in 80-90% of the patients 13,15,17 . More than half of these patients had LVI, and the predominant histological grade was G2 [8][9][10][11][12][13]15,17 .…”

“…According to the immunohistochemical evaluation of the patients, 83-96% had ER+, 81-96% had PR+, and 10.6-35.1% were HER2 positive, and the most common histological type was IDC, which was observed in 80-90% of the patients 13,15,17 . More than half of these patients had LVI, and the predominant histological grade was G2 [8][9][10][11][12][13]15,17 . In terms of histopathological evaluation and surgical treatment, our results are in accordance with the literature.…”

Effect of demethyltransferase FTO on tumor progression

“…In China, BC is now considered as the second leading health burden in terms of incidence next to lung cancer, colorectal cancer, and gastric cancer. The risk factors of BC included genetic predisposition (Braithwaite et al, 2018), age (Spreafico et al, 2020), reproductive and hormonal factors (Fan et al, 2014;Nelson et al, 2012;Sun et al, 2017), obesity (Eliassen et al, 2006;Jiralerspong and Goodwin, 2016), and unhealthy lifestyles (Nelson et al, 2012;Kerr et al, 2017). Distant metastases and chemoresistance are a few major contributors to the surging mortality rate of BC patients.…”

Cáncer de mama en hombre. Reporte de caso

“…El factor de riesgo más crítico es una historia familiar positiva de cáncer de mama: el riesgo se duplica si la historia es positiva para los familiares de primer grado y se quintuplica si hay otros familiares de primer grado afectados. 3 El cáncer de mama en hombres se presenta con más frecuencia en pacientes con receptores de estrógeno (ER) positivo. 4 En la actualidad se ha agregado como opción de tratamiento para el cáncer de mama en hombres la terapia endocrina neoadyuvante a base de tamoxifeno.…”